Updates are available Correction dated 2025-06-11
Click to view Correction: https://doi.org/10.1038/s41591-025-03824-2
-
Authors
Bagley, Stephen J. https://orcid.org/0000-0002-7117-0539
Desai, Arati S.
Fraietta, Joseph A.
Silverbush, Dana
Chafamo, Daniel https://orcid.org/0009-0001-8877-5913
Freeburg, Nelson F.
Gopikrishna, Gayathri Konanur
Rech, Andrew J.
Nabavizadeh, Ali https://orcid.org/0000-0002-0380-4552
Bagley, Linda J.
Park, Jungmin
Jarocha, Danuta
Martins, Rene
Sarmiento, Nicolas
Maloney, Eileen
Lledo, Lester
Stein, Carly
Marshall, Amy
Leskowitz, Rachel M. https://orcid.org/0000-0003-0583-8446
Jadlowsky, Julie K. https://orcid.org/0009-0005-5115-1321
Mackey, Shane
Christensen, Shannon https://orcid.org/0009-0000-4419-1425
Oner, Bike Su https://orcid.org/0009-0008-7051-9584
Plesa, Gabriela
Brennan, Andrea
Gonzalez, Vanessa
Chen, Fang https://orcid.org/0000-0002-1719-3887
Barrett, David
Colbourn, Robert https://orcid.org/0000-0002-8398-3326
Nasrallah, MacLean P. https://orcid.org/0000-0003-4861-0898
Mourelatos, Zissimos
Hwang, Wei-Ting https://orcid.org/0000-0003-2829-2167
Alanio, Cecile https://orcid.org/0000-0003-2785-7445
Siegel, Donald L. https://orcid.org/0000-0003-2098-2251
June, Carl H. https://orcid.org/0000-0003-0241-3557
Hexner, Elizabeth O. https://orcid.org/0000-0002-1125-4060
Binder, Zev A.
O’Rourke, Donald M. https://orcid.org/0000-0002-8479-7314
-
Funding
Funding for this research was provided by:
Gilead Sciences
- License Information
-
More Information
Article History
Received: 2 April 2025
Accepted: 29 April 2025
First Online: 1 June 2025
Competing interests
: S.J.B. has received consulting fees from Modifi Bio, Telix, Servier, Kiyatec, Novocure and Bayer and has received research funding from Kite (a Gilead Company) related to the submitted work and from Incyte, Novocure, GSK and Eli Lilly, all outside of the submitted work. J.A.F. is a member of the scientific advisory boards of Cartography Bio and Shennon Biotechnologies Inc and has patents, royalties and other intellectual property. A.J.R. is a cofounder and shareholder in Cellformatica. J.J. has received consulting fees from Bluewhale Bio, outside of the submitted work. D.B. is an employee of Kite Pharma (a Gilead company). D.L.S. holds founder’s equity and has licensed intellectual property to Verismo Therapeutics and Vetigenics, Inc. and has intellectual property licensing to Chimeric Therapeutics, Ltd. C.H.J. and the University of Pennsylvania have patents pending or issued related to the use of gene modification in T cells for adoptive T cell therapy. C.H.J. is a cofounder of Tmunity (acquired by Kite Pharma, a Gilead company); is a scientific cofounder and holds equity in Capstan Therapeutics, Dispatch Biotherapeutics and Bluewhale Bio; serves on the board of AC Immune; is a scientific advisor to BluesphereBio, Cabaletta, Carisma, Cartography, Cellares, Cellcarta, Celldex, Danaher, Decheng, ImmuneSensor, Kite, Poseida, Verismo, Viracta, Vittoria Bio and WIRB-Copernicus group; and is an inventor on patents and/or patent applications licensed to Novartis Institutes of Biomedical Research and Kite and may receive license revenue from such licenses. Z.A.B. has received research funding from Kite Pharma, has inventorship interest in intellectual property owned by the University of Pennsylvania and has received royalties related to CAR T therapy in solid tumors. D.M.O. reports previous or active roles as consultant and scientific advisory board member for Celldex Therapeutics, Prescient Therapeutics, Century Therapeutics and Chimeric Therapeutics, and has an advisory role and holds equity in Kiragen and Cellula Therapeutics. He has received research funding from Celldex Therapeutics, Novartis, Tmunity Therapeutics and Gilead Sciences/ Kite Pharma. D.M.O. is an inventor of intellectual property (US patent numbers 7,625,558 and 6,417,168 and related families) and has received royalties related to targeted ErbB therapy in solid cancers previously licensed by the University of Pennsylvania. D.M.O. is also an inventor on multiple patents related to CART cell therapy in solid tumors that have been licensed by the University of Pennsylvania and has received royalties from these license agreements. The other authors declare no competing interests.
